SCHEMBL17217397

SCHEMBL17217397

CCc1ccc(CON=[C]c2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.43
▸ RAB9A P51151 5/20 0.40
▸ NPC1 O15118 4/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ GAA P10253 1/20 0.39
▸ RXRA P19793 1/20 0.38
▸ RXRB P28702 1/20 0.38
▸ CYP2A6 P11509 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ TUBB4A P04350 1/20 0.34
▸ TUBB P07437 1/20 0.34
▸ TUBA3C P0DPH7 1/20 0.34
▸ TUBA1B P68363 1/20 0.34
▸ TUBA4A P68366 1/20 0.34
▸ TUBB4B P68371 1/20 0.34
▸ TUBB3 Q13509 1/20 0.34
▸ TUBB2A Q13885 1/20 0.34
▸ TUBB8 Q3ZCM7 1/20 0.34
▸ TUBA3E Q6PEY2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17217395 1.00 TP53 (0.43) TP53RAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL17218644 0.95 TP53 (0.47) TP53RAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL17218641 0.95 TP53 (0.47) TP53RAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL17216623 0.91 CYP2A6 (0.45) TP53RAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL17216620 0.91 CYP2A6 (0.45) TP53RAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL17215728 0.91 IDO1 (0.42) TP53RAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL17215731 0.91 IDO1 (0.42) TP53RAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL17219268 0.87 TSHR (0.44) RAB9ANPC1SMN1; SMN2L3MBTL1GAA
SCHEMBL4196342 0.87 TSHR (0.44) RAB9ANPC1SMN1; SMN2L3MBTL1GAA
SCHEMBL4196340 0.87 TSHR (0.44) RAB9ANPC1SMN1; SMN2L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 TP53 4563/4885RAB9A 399/4885NPC1 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback